Healthy pipeline for cancer treatments: PhRMA

Share this article:
A report delivered by industry trade group PhRMA has found a record 750 potential cancer treatments in the US research pipeline, according to a statement.

The report was released in Baton Rouge, LA, where it had “particular relevance,” according to PhRMA senior vice president Ken Johnnson. “According to the Centers for Disease Control and Prevention, Louisiana has the highest death rate from cancer in the United States,” said Johnson.  

Billy Tauzin, PhRMA president, CEO and formerly a US Representative of Louisiana's 3rd congressional district, noted the strong commitment by America's pharmaceutical research companies. “The medicines now in the research pipeline will add to the substantial progress made in the last five years by biopharmaceutical companies in developing new and more effective cancer treatments,” he said.

Among cancer treatments in the pipeline, 113 are for lung cancer, 90 for breast cancer, 65 for colorectal cancer and 88 for prostate cancer, according to a statement. 

In 2008, it is estimated that 294,120 men and 271,530 women will die from cancer in the US, according to the American Cancer Society.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.